Keyman188 welcome all come to HLCap to give more & more negative speech...


So let Keyman188 can accumulate more & more...better below 3.00...kekeke...kekeke...

Aiyo...Keyman188 only afford to buy bicycle only mahh....



Posted by AlvinTSK > Dec 19, 2020 12:13 PM | Report Abuse

Laugh all you want Keyman ... In the end, you are irrelevant and nobody care about you !! Just another cheap skate trying to buy a mercedes car but can only afford to pay a kancil price !!

What the Keyman188 always highlighted...


https://klse.i3investor.com/servlets/forum/800001029.jsp


You all see HLCap, also all the way down from 9.00 ++ to current level 6.3++....


Even though Keyman188's invested HLCap dip until below 3.00, Keyman188 should be very very excited until bet in until no sky...kekeke...kekeke...


But you deserve to believe, why so worry share price keep on dropping !!!......


unless you all also started to doubt your own perception & decision!!!

Trump signs two-day funding bill as Congress rushes to finalize spending, Covid relief deal

(PUBLISHED FRI, DEC 18 20206:13 PM ESTUPDATED FRI, DEC 18 202010:30 PM EST)

~ Trump signs a two-day government funding bill just hours before a shutdown deadline.

~ Lawmakers hope to buy more time to finalize a $900 billion coronavirus relief package.

~ They aim to tie it to a full-year government spending bill.


President Donald Trump signed a two-day government funding bill into law Friday night as Congress tries to buy time to strike a spending and coronavirus relief deal.

The president inked the legislation to keep the government running about an hour-and-a-half before a midnight deadline to pass spending legislation. The stopgap measure would fund federal operations through Sunday until 12:01 a.m. ET Monday morning while congressional leaders try to finalize a full-year funding and coronavirus relief package.

Even after lawmakers avoided a shutdown, Congress again finds itself on a tight deadline. The House will meet again on Sunday at noon ET and will not vote earlier than 1 p.m. The Senate will return at 11 a.m. ET Saturday and will likely address nominations.

Senators including independent Bernie Sanders of Vermont and Republican Josh Hawley of Missouri had warned they could delay approval of a spending bill as they lobby for leadership to include a $1,200 direct payment in a pandemic aid package. Neither lawmaker followed through on the warning.

Before the Senate unanimously passed the spending bill, Sanders said he would “object to any attempt” by the chamber to pass a full-year spending plan without also approving a pandemic relief package that includes “substantial direct payments.”

Hawley earlier tweeted that he would not block the legislation after top Republicans assured him a final relief deal would include “direct assistance to working people.” Lawmakers are expected to include $600 payments, down from the $1,200 checks approved as part of the CARES Act in March.

The House initially tried to pass the funding bill unanimously on Friday. However, Rep. Chip Roy, R-Texas, objected and forced a full recorded vote.

The move delayed the bill’s passage by more than an hour as Congress worked on a tight schedule to beat the shutdown deadline. The House approved it in a 320-60 vote.

Lawmakers, for the second time this month, aim to give themselves more time to package a full-year spending bill and money to lift a health-care system and economy buckling under a relentless coronavirus outbreak. They already approved a one-week extension that kept the lights on through Friday.

Congressional leaders have said for days that they are close to a desperately needed pandemic aid agreement. However, they have failed to iron out the final details of a $900 billion package.

Millions of Americans await help as the virus overwhelms hospitals and health-care workers. Covid-19 now kills thousands of Americans every week.

New economic restrictions to contain the outbreak have sharpened pain for people already scrambling to afford food and housing.

A Republican-backed proposal to limit the Federal Reserve’s emergency lending power now poses the biggest roadblock to a deal. Democrats say the measure would hamstring President-elect Joe Biden’s ability to respond to the ongoing economic crisis after he takes office on Jan. 20.

Along with direct payments, the developing plan would include a $300 per week federal unemployment supplement. It would extend a pandemic-era expansion of jobless benefits, which 12 million people would lose the day after Christmas.

It is unclear now how the proposal would handle a federal eviction moratorium. The provision lapses at the end of the year, potentially leaving millions vulnerable to eviction.

The package would put at least $300 billion into small business aid. It would include money for Covid-19 vaccine distribution and testing, along with relief for hospitals.

It would also direct funding to schools, which have had to adapt to stay open or go virtual during the pandemic.

The bill will not address state and local government support or liability protections for businesses. Those issues divided Democratic and Republican leaders.

Democrats and many rank-and-file GOP lawmakers, along with bipartisan governors, supported state and local aid as necessary to preserve first-responder jobs and allow officials to contain the pandemic. The GOP argued legal immunity would protect small businesses from frivolous litigation.

##https://www.cnbc.com/2020/12/18/covid-stimulus-update-house-passes-short-term-funding-bill-to-prevent-government-shutdown.html

Post removed.Why?

Aiyo...Keyman188 not professional mahhh......

Let the Professionals tell the market "Final Truth" lorrr......

PublicInvest Research downgrades Top Glove to 'neutral' on ESG concerns

(theedgemarkets.com / December 18, 2020 10:38 am +08)


KUALA LUMPUR (Dec 18): PublicInvest Research has downgraded Top Glove Corp Bhd’s rating to "neutral" from "trading buy" as it lowered its target price (TP) to RM7.30 from RM9.70 as concerns remained over environmental, social and governance (ESG)-related issues.

The research house’s analyst Chua Siu Li said in a note today that she did not discount the fact that glove makers like Top Glove will continue to deliver record-breaking profit for the coming quarters as average selling prices (ASPs) are expected to increase by another 30% quarter-on-quarter (q-o-q) in the second quarter ending Feb 28, 2021 (2QFY21).

“However, with the ESG issues uncovered recently, we are incorporating a 20% ESG discount to our valuation of Top Glove, from a price-earnings multiple of 10.5 times previously, to eight times currently (at its five-year historical mean), taking into account lingering concerns over ESG-related issues,” she said, adding that her TP was subsequently lowered to RM7.30.

Chua cited Top Glove's numerous ESG-related issues that had made headlines, such as its failure to provide adequate accommodation for its factory workers as well as the sacking of a whistle-blower who had shared photographs showing a lack of physical distancing among workers outside its factories.

##https://www.theedgemarkets.com/article/publicinvest-research-downgrades-top-glove-neutral-esg-concerns

FDA approves second Covid vaccine for emergency use as it clears Moderna’s for U.S. distribution

(PUBLISHED FRI, DEC 18 20207:38 PM ESTUPDATED FRI, DEC 18 20207:59 PM EST)

~ Moderna’s Covid-19 vaccine is the second approved for use in the U.S.

~ It will bolster the number of available doses, which states desperately need to fend off the pandemic.

~ The U.S. plans to distribute roughly 5.9 million doses of Moderna’s vaccine to 64 states, territories and major cities across the nation next week.

The Food and Drug Administration has approved Moderna’s coronavirus vaccine for emergency use. The vaccine — the second approved for use in the U.S. behind Pfizer and BioNTech’s — bolsters the U.S. supply of doses. The potentially lifesaving shots are desperately needed to fend off the pandemic that has taken more than 300,000 American lives and overwhelmed hospitals.

The FDA’s emergency use authorization Friday approves the federal government’s plan to distribute roughly 5.9 million doses of Moderna’s vaccine to 64 states, territories and major cities across the nation next week.

“We likely will see shots in the arm by the very early part of next week, I would hope Monday or Tuesday,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said on the “Today” show on Friday morning.

Cont...

##https://www.cnbc.com/2020/12/18/moderna-covid-vaccine-approved-fda-for-emergency-use.html

FDA approves second Covid vaccine for emergency use as it clears Moderna’s for U.S. distribution

(PUBLISHED FRI, DEC 18 20207:38 PM ESTUPDATED FRI, DEC 18 20207:59 PM EST)

~ Moderna’s Covid-19 vaccine is the second approved for use in the U.S.

~ It will bolster the number of available doses, which states desperately need to fend off the pandemic.

~ The U.S. plans to distribute roughly 5.9 million doses of Moderna’s vaccine to 64 states, territories and major cities across the nation next week.

The Food and Drug Administration has approved Moderna’s coronavirus vaccine for emergency use. The vaccine — the second approved for use in the U.S. behind Pfizer and BioNTech’s — bolsters the U.S. supply of doses. The potentially lifesaving shots are desperately needed to fend off the pandemic that has taken more than 300,000 American lives and overwhelmed hospitals.

The FDA’s emergency use authorization Friday approves the federal government’s plan to distribute roughly 5.9 million doses of Moderna’s vaccine to 64 states, territories and major cities across the nation next week.

“We likely will see shots in the arm by the very early part of next week, I would hope Monday or Tuesday,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said on the “Today” show on Friday morning.

In addition to Moderna’s vaccine, the U.S. also plans to send out 2 million doses of Pfizer’s vaccine after 2.9 million doses were cleared for shipment this week, Gen. Gustave Perna, who oversees logistics for the Operation Warp Speed vaccine project, said Monday. Both vaccines require two doses three to four weeks apart. Moderna’s Covid vaccine is its first-ever FDA authorized product.

“With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day,” FDA Commissioner Dr. Stephen Hahn said in a statement.

U.S. officials hope to vaccinate at least 20 million Americans — mostly front-line health-care workers and nursing home residents — by the end of the year. Initial doses will be limited as manufacturing ramps up, with officials predicting it will take months to immunize everyone in the U.S. who wants to be vaccinated. The Centers for Disease Control and Prevention has provided states with an outline that recommends prioritizing health workers and nursing homes, but states can distribute the vaccine as they see fit.

Already, states are reporting confusion about vaccine plans. In recent days, state officials said they learned their second shipment of Pfizer’s vaccine would be smaller than expected or delayed. In Florida, for example, Republican Gov. Ron DeSantis said the federal government told him the state would receive 205,000 Pfizer vaccine doses next week and 247,000 the following week. Those shipments are now on hold, DeSantis said at a press conference Tuesday, and it’s unclear when they will arrive.

Moderna’s vaccine, like Pfizer’s, uses messenger RNA, or mRNA, technology. It’s a new approach to vaccines that uses genetic material to provoke an immune response. Late-stage clinical trial data published last month shows Moderna’s vaccine is more than 94% effective in preventing Covid, is safe and appears to fend off severe disease. To achieve maximum effectiveness, the vaccine requires two doses taken four weeks apart.

The FDA has indicated it would authorize a Covid-19 vaccine that’s safe and at least 50% effective. The flu vaccine, by comparison, generally reduces people’s risk of getting influenza by 40% to 60% compared with people who aren’t inoculated, according to the CDC.

Cont...

##https://www.cnbc.com/2020/12/18/moderna-covid-vaccine-approved-fda-for-emergency-use.html

FDA approves second Covid vaccine for emergency use as it clears Moderna’s for U.S. distribution

(PUBLISHED FRI, DEC 18 20207:38 PM ESTUPDATED FRI, DEC 18 20207:59 PM EST)

~ Moderna’s Covid-19 vaccine is the second approved for use in the U.S.

~ It will bolster the number of available doses, which states desperately need to fend off the pandemic.

~ The U.S. plans to distribute roughly 5.9 million doses of Moderna’s vaccine to 64 states, territories and major cities across the nation next week.

The Food and Drug Administration has approved Moderna’s coronavirus vaccine for emergency use. The vaccine — the second approved for use in the U.S. behind Pfizer and BioNTech’s — bolsters the U.S. supply of doses. The potentially lifesaving shots are desperately needed to fend off the pandemic that has taken more than 300,000 American lives and overwhelmed hospitals.

The FDA’s emergency use authorization Friday approves the federal government’s plan to distribute roughly 5.9 million doses of Moderna’s vaccine to 64 states, territories and major cities across the nation next week.

“We likely will see shots in the arm by the very early part of next week, I would hope Monday or Tuesday,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said on the “Today” show on Friday morning.

In addition to Moderna’s vaccine, the U.S. also plans to send out 2 million doses of Pfizer’s vaccine after 2.9 million doses were cleared for shipment this week, Gen. Gustave Perna, who oversees logistics for the Operation Warp Speed vaccine project, said Monday. Both vaccines require two doses three to four weeks apart. Moderna’s Covid vaccine is its first-ever FDA authorized product.

“With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day,” FDA Commissioner Dr. Stephen Hahn said in a statement.

U.S. officials hope to vaccinate at least 20 million Americans — mostly front-line health-care workers and nursing home residents — by the end of the year. Initial doses will be limited as manufacturing ramps up, with officials predicting it will take months to immunize everyone in the U.S. who wants to be vaccinated. The Centers for Disease Control and Prevention has provided states with an outline that recommends prioritizing health workers and nursing homes, but states can distribute the vaccine as they see fit.

Already, states are reporting confusion about vaccine plans. In recent days, state officials said they learned their second shipment of Pfizer’s vaccine would be smaller than expected or delayed. In Florida, for example, Republican Gov. Ron DeSantis said the federal government told him the state would receive 205,000 Pfizer vaccine doses next week and 247,000 the following week. Those shipments are now on hold, DeSantis said at a press conference Tuesday, and it’s unclear when they will arrive.

Moderna’s vaccine, like Pfizer’s, uses messenger RNA, or mRNA, technology. It’s a new approach to vaccines that uses genetic material to provoke an immune response. Late-stage clinical trial data published last month shows Moderna’s vaccine is more than 94% effective in preventing Covid, is safe and appears to fend off severe disease. To achieve maximum effectiveness, the vaccine requires two doses taken four weeks apart.

The FDA has indicated it would authorize a Covid-19 vaccine that’s safe and at least 50% effective. The flu vaccine, by comparison, generally reduces people’s risk of getting influenza by 40% to 60% compared with people who aren’t inoculated, according to the CDC.

Cont...

##https://www.cnbc.com/2020/12/18/moderna-covid-vaccine-approved-fda-for-emergency-use.html

FDA approves second Covid vaccine for emergency use as it clears Moderna’s for U.S. distribution

(PUBLISHED FRI, DEC 18 20207:38 PM ESTUPDATED FRI, DEC 18 20207:59 PM EST)

~ Moderna’s Covid-19 vaccine is the second approved for use in the U.S.

~ It will bolster the number of available doses, which states desperately need to fend off the pandemic.

~ The U.S. plans to distribute roughly 5.9 million doses of Moderna’s vaccine to 64 states, territories and major cities across the nation next week.

The Food and Drug Administration has approved Moderna’s coronavirus vaccine for emergency use. The vaccine — the second approved for use in the U.S. behind Pfizer and BioNTech’s — bolsters the U.S. supply of doses. The potentially lifesaving shots are desperately needed to fend off the pandemic that has taken more than 300,000 American lives and overwhelmed hospitals.

The FDA’s emergency use authorization Friday approves the federal government’s plan to distribute roughly 5.9 million doses of Moderna’s vaccine to 64 states, territories and major cities across the nation next week.

“We likely will see shots in the arm by the very early part of next week, I would hope Monday or Tuesday,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said on the “Today” show on Friday morning.

In addition to Moderna’s vaccine, the U.S. also plans to send out 2 million doses of Pfizer’s vaccine after 2.9 million doses were cleared for shipment this week, Gen. Gustave Perna, who oversees logistics for the Operation Warp Speed vaccine project, said Monday. Both vaccines require two doses three to four weeks apart. Moderna’s Covid vaccine is its first-ever FDA authorized product.

“With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day,” FDA Commissioner Dr. Stephen Hahn said in a statement.

U.S. officials hope to vaccinate at least 20 million Americans — mostly front-line health-care workers and nursing home residents — by the end of the year. Initial doses will be limited as manufacturing ramps up, with officials predicting it will take months to immunize everyone in the U.S. who wants to be vaccinated. The Centers for Disease Control and Prevention has provided states with an outline that recommends prioritizing health workers and nursing homes, but states can distribute the vaccine as they see fit.

Already, states are reporting confusion about vaccine plans. In recent days, state officials said they learned their second shipment of Pfizer’s vaccine would be smaller than expected or delayed. In Florida, for example, Republican Gov. Ron DeSantis said the federal government told him the state would receive 205,000 Pfizer vaccine doses next week and 247,000 the following week. Those shipments are now on hold, DeSantis said at a press conference Tuesday, and it’s unclear when they will arrive.

Moderna’s vaccine, like Pfizer’s, uses messenger RNA, or mRNA, technology. It’s a new approach to vaccines that uses genetic material to provoke an immune response. Late-stage clinical trial data published last month shows Moderna’s vaccine is more than 94% effective in preventing Covid, is safe and appears to fend off severe disease. To achieve maximum effectiveness, the vaccine requires two doses taken four weeks apart.

The FDA has indicated it would authorize a Covid-19 vaccine that’s safe and at least 50% effective. The flu vaccine, by comparison, generally reduces people’s risk of getting influenza by 40% to 60% compared with people who aren’t inoculated, according to the CDC.

The FDA authorized Moderna’s vaccine for people who are 18 years old and older. Such an authorization from the agency isn’t the same as full approval, which requires more data and can typically take several months longer. Moderna has submitted only two months of follow-up safety data. The agency usually requires six months for full approval and can always revoke an EUA for a drug if it doesn’t work as intended or proves to be unsafe. The FDA approved the emergency use of hydroxychloroquine to treat Covid-19 in March, only to revoke it in June after additional data showed it provided “no evidence of benefit” in coronavirus patients.

Cont...

##https://www.cnbc.com/2020/12/18/moderna-covid-vaccine-approved-fda-for-emergency-use.html

FDA approves second Covid vaccine for emergency use as it clears Moderna’s for U.S. distribution

(PUBLISHED FRI, DEC 18 20207:38 PM ESTUPDATED FRI, DEC 18 20207:59 PM EST)

~ Moderna’s Covid-19 vaccine is the second approved for use in the U.S.

~ It will bolster the number of available doses, which states desperately need to fend off the pandemic.

~ The U.S. plans to distribute roughly 5.9 million doses of Moderna’s vaccine to 64 states, territories and major cities across the nation next week.

The Food and Drug Administration has approved Moderna’s coronavirus vaccine for emergency use. The vaccine — the second approved for use in the U.S. behind Pfizer and BioNTech’s — bolsters the U.S. supply of doses. The potentially lifesaving shots are desperately needed to fend off the pandemic that has taken more than 300,000 American lives and overwhelmed hospitals.

The FDA’s emergency use authorization Friday approves the federal government’s plan to distribute roughly 5.9 million doses of Moderna’s vaccine to 64 states, territories and major cities across the nation next week.

“We likely will see shots in the arm by the very early part of next week, I would hope Monday or Tuesday,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said on the “Today” show on Friday morning.

In addition to Moderna’s vaccine, the U.S. also plans to send out 2 million doses of Pfizer’s vaccine after 2.9 million doses were cleared for shipment this week, Gen. Gustave Perna, who oversees logistics for the Operation Warp Speed vaccine project, said Monday. Both vaccines require two doses three to four weeks apart. Moderna’s Covid vaccine is its first-ever FDA authorized product.

“With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day,” FDA Commissioner Dr. Stephen Hahn said in a statement.

U.S. officials hope to vaccinate at least 20 million Americans — mostly front-line health-care workers and nursing home residents — by the end of the year. Initial doses will be limited as manufacturing ramps up, with officials predicting it will take months to immunize everyone in the U.S. who wants to be vaccinated. The Centers for Disease Control and Prevention has provided states with an outline that recommends prioritizing health workers and nursing homes, but states can distribute the vaccine as they see fit.

Already, states are reporting confusion about vaccine plans. In recent days, state officials said they learned their second shipment of Pfizer’s vaccine would be smaller than expected or delayed. In Florida, for example, Republican Gov. Ron DeSantis said the federal government told him the state would receive 205,000 Pfizer vaccine doses next week and 247,000 the following week. Those shipments are now on hold, DeSantis said at a press conference Tuesday, and it’s unclear when they will arrive.

Moderna’s vaccine, like Pfizer’s, uses messenger RNA, or mRNA, technology. It’s a new approach to vaccines that uses genetic material to provoke an immune response. Late-stage clinical trial data published last month shows Moderna’s vaccine is more than 94% effective in preventing Covid, is safe and appears to fend off severe disease. To achieve maximum effectiveness, the vaccine requires two doses taken four weeks apart.

The FDA has indicated it would authorize a Covid-19 vaccine that’s safe and at least 50% effective. The flu vaccine, by comparison, generally reduces people’s risk of getting influenza by 40% to 60% compared with people who aren’t inoculated, according to the CDC.

The FDA authorized Moderna’s vaccine for people who are 18 years old and older. Such an authorization from the agency isn’t the same as full approval, which requires more data and can typically take several months longer. Moderna has submitted only two months of follow-up safety data. The agency usually requires six months for full approval and can always revoke an EUA for a drug if it doesn’t work as intended or proves to be unsafe. The FDA approved the emergency use of hydroxychloroquine to treat Covid-19 in March, only to revoke it in June after additional data showed it provided “no evidence of benefit” in coronavirus patients.

Cont...

##https://www.cnbc.com/2020/12/18/moderna-covid-vaccine-approved-fda-for-emergency-use.html

FDA approves second Covid vaccine for emergency use as it clears Moderna’s for U.S. distribution

(PUBLISHED FRI, DEC 18 20207:38 PM ESTUPDATED FRI, DEC 18 20207:59 PM EST)

~ Moderna’s Covid-19 vaccine is the second approved for use in the U.S.

~ It will bolster the number of available doses, which states desperately need to fend off the pandemic.

~ The U.S. plans to distribute roughly 5.9 million doses of Moderna’s vaccine to 64 states, territories and major cities across the nation next week.

The Food and Drug Administration has approved Moderna’s coronavirus vaccine for emergency use. The vaccine — the second approved for use in the U.S. behind Pfizer and BioNTech’s — bolsters the U.S. supply of doses. The potentially lifesaving shots are desperately needed to fend off the pandemic that has taken more than 300,000 American lives and overwhelmed hospitals.

The FDA’s emergency use authorization Friday approves the federal government’s plan to distribute roughly 5.9 million doses of Moderna’s vaccine to 64 states, territories and major cities across the nation next week.

“We likely will see shots in the arm by the very early part of next week, I would hope Monday or Tuesday,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said on the “Today” show on Friday morning.

In addition to Moderna’s vaccine, the U.S. also plans to send out 2 million doses of Pfizer’s vaccine after 2.9 million doses were cleared for shipment this week, Gen. Gustave Perna, who oversees logistics for the Operation Warp Speed vaccine project, said Monday. Both vaccines require two doses three to four weeks apart. Moderna’s Covid vaccine is its first-ever FDA authorized product.

“With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day,” FDA Commissioner Dr. Stephen Hahn said in a statement.

U.S. officials hope to vaccinate at least 20 million Americans — mostly front-line health-care workers and nursing home residents — by the end of the year. Initial doses will be limited as manufacturing ramps up, with officials predicting it will take months to immunize everyone in the U.S. who wants to be vaccinated. The Centers for Disease Control and Prevention has provided states with an outline that recommends prioritizing health workers and nursing homes, but states can distribute the vaccine as they see fit.

Already, states are reporting confusion about vaccine plans. In recent days, state officials said they learned their second shipment of Pfizer’s vaccine would be smaller than expected or delayed. In Florida, for example, Republican Gov. Ron DeSantis said the federal government told him the state would receive 205,000 Pfizer vaccine doses next week and 247,000 the following week. Those shipments are now on hold, DeSantis said at a press conference Tuesday, and it’s unclear when they will arrive.

Moderna’s vaccine, like Pfizer’s, uses messenger RNA, or mRNA, technology. It’s a new approach to vaccines that uses genetic material to provoke an immune response. Late-stage clinical trial data published last month shows Moderna’s vaccine is more than 94% effective in preventing Covid, is safe and appears to fend off severe disease. To achieve maximum effectiveness, the vaccine requires two doses taken four weeks apart.

The FDA has indicated it would authorize a Covid-19 vaccine that’s safe and at least 50% effective. The flu vaccine, by comparison, generally reduces people’s risk of getting influenza by 40% to 60% compared with people who aren’t inoculated, according to the CDC.

The FDA authorized Moderna’s vaccine for people who are 18 years old and older. Such an authorization from the agency isn’t the same as full approval, which requires more data and can typically take several months longer. Moderna has submitted only two months of follow-up safety data. The agency usually requires six months for full approval and can always revoke an EUA for a drug if it doesn’t work as intended or proves to be unsafe. The FDA approved the emergency use of hydroxychloroquine to treat Covid-19 in March, only to revoke it in June after additional data showed it provided “no evidence of benefit” in coronavirus patients.

The FDA’s announcement comes after a key agency advisory panel on Thursday voted 20-0 with one abstention to recommend the vaccine for emergency use. The Vaccines and Related Biological Products Advisory Committee plays a key role in approving flu and other vaccines in the U.S., verifying the shots are safe for public use. While the FDA doesn’t have to follow the advisory committee’s recommendation, it often does.

Cont...

##https://www.cnbc.com/2020/12/18/moderna-covid-vaccine-approved-fda-for-emergency-use.html

FDA approves second Covid vaccine for emergency use as it clears Moderna’s for U.S. distribution

(PUBLISHED FRI, DEC 18 20207:38 PM ESTUPDATED FRI, DEC 18 20207:59 PM EST)

~ Moderna’s Covid-19 vaccine is the second approved for use in the U.S.

~ It will bolster the number of available doses, which states desperately need to fend off the pandemic.

~ The U.S. plans to distribute roughly 5.9 million doses of Moderna’s vaccine to 64 states, territories and major cities across the nation next week.

The Food and Drug Administration has approved Moderna’s coronavirus vaccine for emergency use. The vaccine — the second approved for use in the U.S. behind Pfizer and BioNTech’s — bolsters the U.S. supply of doses. The potentially lifesaving shots are desperately needed to fend off the pandemic that has taken more than 300,000 American lives and overwhelmed hospitals.

The FDA’s emergency use authorization Friday approves the federal government’s plan to distribute roughly 5.9 million doses of Moderna’s vaccine to 64 states, territories and major cities across the nation next week.

“We likely will see shots in the arm by the very early part of next week, I would hope Monday or Tuesday,” Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said on the “Today” show on Friday morning.

In addition to Moderna’s vaccine, the U.S. also plans to send out 2 million doses of Pfizer’s vaccine after 2.9 million doses were cleared for shipment this week, Gen. Gustave Perna, who oversees logistics for the Operation Warp Speed vaccine project, said Monday. Both vaccines require two doses three to four weeks apart. Moderna’s Covid vaccine is its first-ever FDA authorized product.

“With the availability of two vaccines now for the prevention of COVID-19, the FDA has taken another crucial step in the fight against this global pandemic that is causing vast numbers of hospitalizations and deaths in the United States each day,” FDA Commissioner Dr. Stephen Hahn said in a statement.

U.S. officials hope to vaccinate at least 20 million Americans — mostly front-line health-care workers and nursing home residents — by the end of the year. Initial doses will be limited as manufacturing ramps up, with officials predicting it will take months to immunize everyone in the U.S. who wants to be vaccinated. The Centers for Disease Control and Prevention has provided states with an outline that recommends prioritizing health workers and nursing homes, but states can distribute the vaccine as they see fit.

Already, states are reporting confusion about vaccine plans. In recent days, state officials said they learned their second shipment of Pfizer’s vaccine would be smaller than expected or delayed. In Florida, for example, Republican Gov. Ron DeSantis said the federal government told him the state would receive 205,000 Pfizer vaccine doses next week and 247,000 the following week. Those shipments are now on hold, DeSantis said at a press conference Tuesday, and it’s unclear when they will arrive.

Moderna’s vaccine, like Pfizer’s, uses messenger RNA, or mRNA, technology. It’s a new approach to vaccines that uses genetic material to provoke an immune response. Late-stage clinical trial data published last month shows Moderna’s vaccine is more than 94% effective in preventing Covid, is safe and appears to fend off severe disease. To achieve maximum effectiveness, the vaccine requires two doses taken four weeks apart.

The FDA has indicated it would authorize a Covid-19 vaccine that’s safe and at least 50% effective. The flu vaccine, by comparison, generally reduces people’s risk of getting influenza by 40% to 60% compared with people who aren’t inoculated, according to the CDC.

The FDA authorized Moderna’s vaccine for people who are 18 years old and older. Such an authorization from the agency isn’t the same as full approval, which requires more data and can typically take several months longer. Moderna has submitted only two months of follow-up safety data. The agency usually requires six months for full approval and can always revoke an EUA for a drug if it doesn’t work as intended or proves to be unsafe. The FDA approved the emergency use of hydroxychloroquine to treat Covid-19 in March, only to revoke it in June after additional data showed it provided “no evidence of benefit” in coronavirus patients.

The FDA’s announcement comes after a key agency advisory panel on Thursday voted 20-0 with one abstention to recommend the vaccine for emergency use. The Vaccines and Related Biological Products Advisory Committee plays a key role in approving flu and other vaccines in the U.S., verifying the shots are safe for public use. While the FDA doesn’t have to follow the advisory committee’s recommendation, it often does.

Cont...

##https://www.cnbc.com/2020/12/18/moderna-covid-vaccine-approved-fda-for-emergency-use.html

Stocks close at record highs as traders bet that a fiscal stimulus deal is coming

(PUBLISHED WED, DEC 16 20206:00 PM ESTUPDATED THU, DEC 17 20205:43 PM EST)

Stocks closed at record levels on Thursday, boosted by hope of Washington coming through on additional fiscal aid before the end of 2020.

The S&P 500 gained 0.6% to end the day at 3,722.48, and the tech-heavy Nasdaq Composite advanced 0.8% to 12,764.75. The Dow Jones Industrial Average climbed 148.83 points, or 0.5%, to 30,303.37. Both the S&P 500 and Nasdaq hit intraday and closing records. The Dow posted its highest-ever closing level.

Real estate, materials and health care were the best-performing sectors in the S&P 500, rising more than 1% each. Johnson & Johnson rose 2.6% to lead the Dow higher.

“Stimulus is still the main driver in the market right now until they get something done, and it does appear there is some motivation on that front to get something done,” said Dan Deming, managing director at KKM Financial. “The market’s benefiting from that” enthusiasm.

Congressional leaders on Wednesday closed in on a $900 stimulus package that would include direct payments to individuals.

The measure would exclude liability protections for businesses as well as aid to state and local governments, CNBC confirmed. Disagreements over those issues have been a stumbling block in the latest round of negotiations.

Senate Majority Leader Mitch McConnell, R-Ky., said Thursday that a coronavirus relief deal was close at hand.

The latest round of U.S. fiscal stimulus talks comes as Covid-19 cases increase at a record pace. The U.S. is recording at least 215,729 additional Covid-19 cases each day, based on a seven-day average calculated by CNBC using Johns Hopkins University data. On Wednesday alone, more than 247,000 new infections were confirmed.

This resurgence in Covid-19 cases has led to states reimposing stricter social-distancing measures that are slowing down parts of the economy, especially the labor market.

On Thursday, data showed jobless claims totaled 885,000 last week, hitting their highest level since early September. Economists expected 808,000 workers sought state jobless benefits during the week ended Dec. 12.

“Until COVID is more under control, claims are going to continue to be elevated,” Thomas Simons, money market economist at Jefferies, wrote in a note.

Wall Street was coming off a mixed session in which the S&P 500 and Nasdaq Composite rose while the Dow posted a small loss.

On Wednesday, the Federal Reserve pledged to keep buying bonds until the economic recovery was completed. Fed Chairman Jerome Powell also said the central bank would increase its bond purchases if the recovery slows down.

Gregory Faranello, head of U.S. rates trading at AmeriVet Securities, said U.S. monetary policy will likely stay easy for a while.

“They feel that there still are disinflationary forces globally to contend with, and they are being realistic about their timeframe and their ability to achieve their inflation goal” of 2%, Faranello said. “This lends itself to this theme [rates] staying lower-for-longer.”


##https://www.cnbc.com/2020/12/16/stock-market-futures-open-to-close-news.html

##https://www.cnbc.com/2020/12/17/moderna-covid-vaccine-fda-panel-recommends-emergency-approval.html

FDA panel endorses second Covid vaccine in U.S. as Moderna wins key vote in path to emergency use

(PUBLISHED THU, DEC 17 20205:00 PM ESTUPDATED THU, DEC 17 20207:05 PM EST)

~ An influential FDA advisory panel overwhelmingly voted to recommend the approval of Moderna’s coronavirus vaccine for emergency use.

~ The FDA’s Vaccines and Related Biological Products Advisory Committee plays a key role in approving flu and other vaccines in the U.S., verifying the shots are safe for public use.

~ While the FDA doesn’t have to follow the advisory committee’s recommendation, it often does.


An influential Food and Drug Administration advisory panel on Thursday overwhelmingly backed Moderna’s coronavirus vaccine, a key step paving the way to distribute the second Covid-19 vaccine in the United States next week.

The nonbinding decision, which was adopted 20-0 with one abstention, by the FDA’s Vaccines and Related Biological Products Advisory Committee came exactly a week after the outside group of vaccine and infectious disease experts voted to recommend Pfizer and BioNTech’s vaccine for an emergency use authorization, or EUA. The agency granted Pfizer’s EUA the next day, and the first inoculations in the U.S. were given Monday.

The FDA advisory committee plays a key role in approving flu and other vaccines in the U.S., verifying the shots are safe for public use. While the FDA doesn’t have to follow the advisory committee’s recommendation, it often does. The U.S. plans to ship just under 6 million doses next week, pending the agency’s OK, Gen. Gustave Perna, who oversees logistics for the Operation Warp Speed vaccine project, told reporters Monday.

Prior to the vote, some members of the committee stressed that their endorsement for Moderna’s vaccine was not for a full FDA approval, reiterating that the agency will still need to review more data on safety and effectiveness.

“I don’t want people to interpret this the same way they would a licensed vaccine,” said Dr. Cody Meissner, a voting member of the committee and an infectious diseases expert at Tufts University School of Medicine. The endorsement is “based on the available evidence, but that’s limited.”

An EUA means the FDA will allow some people to receive the vaccine as the agency continues to evaluate data. It isn’t the same as full approval, which requires more data and can typically take several months longer. Moderna has submitted only two months of follow-up safety data. The agency usually requires six months for full approval. The committee recommended emergency authorization of the vaccine for people who are 18 years old and older.

Member Dr. Michael Kurilla, an infectious disease expert with the National Institutes of Health, was the only member to not vote yes. He said he decided to abstain because he was “uncomfortable” endorsing the vaccine for everyone age 18 and older.

“In the midst of a pandemic and with limited vaccine supply, a blanket statement for individuals for 18 years and older is just too broad,” said Kurilla. “I’m not convinced for all of those age groups the benefits do actually outweigh the risk.”

Initial doses will be limited as manufacturing ramps up, with officials predicting it will take months to immunize everyone in the U.S. who wants to be vaccinated. The Centers for Disease Control and Prevention has provided states with an outline that recommends prioritizing health-care workers and nursing homes, but states can distribute the vaccine as they see fit.

Moderna’s vaccine uses messenger RNA, or mRNA, technology. It’s a new approach to vaccines that uses genetic material to provoke an immune response. Late-stage clinical trial data shows the vaccine is more than 94% effective in preventing Covid, is safe and appears to fend off severe disease. To achieve maximum effectiveness, the vaccine requires two doses taken four weeks apart.


Cont...

FDA panel endorses second Covid vaccine in U.S. as Moderna wins key vote in path to emergency use

(PUBLISHED THU, DEC 17 20205:00 PM ESTUPDATED THU, DEC 17 20207:05 PM EST)

~ An influential FDA advisory panel overwhelmingly voted to recommend the approval of Moderna’s coronavirus vaccine for emergency use.

~ The FDA’s Vaccines and Related Biological Products Advisory Committee plays a key role in approving flu and other vaccines in the U.S., verifying the shots are safe for public use.

~ While the FDA doesn’t have to follow the advisory committee’s recommendation, it often does.


An influential Food and Drug Administration advisory panel on Thursday overwhelmingly backed Moderna’s coronavirus vaccine, a key step paving the way to distribute the second Covid-19 vaccine in the United States next week.

The nonbinding decision, which was adopted 20-0 with one abstention, by the FDA’s Vaccines and Related Biological Products Advisory Committee came exactly a week after the outside group of vaccine and infectious disease experts voted to recommend Pfizer and BioNTech’s vaccine for an emergency use authorization, or EUA. The agency granted Pfizer’s EUA the next day, and the first inoculations in the U.S. were given Monday.

The FDA advisory committee plays a key role in approving flu and other vaccines in the U.S., verifying the shots are safe for public use. While the FDA doesn’t have to follow the advisory committee’s recommendation, it often does. The U.S. plans to ship just under 6 million doses next week, pending the agency’s OK, Gen. Gustave Perna, who oversees logistics for the Operation Warp Speed vaccine project, told reporters Monday.

Prior to the vote, some members of the committee stressed that their endorsement for Moderna’s vaccine was not for a full FDA approval, reiterating that the agency will still need to review more data on safety and effectiveness.

“I don’t want people to interpret this the same way they would a licensed vaccine,” said Dr. Cody Meissner, a voting member of the committee and an infectious diseases expert at Tufts University School of Medicine. The endorsement is “based on the available evidence, but that’s limited.”

An EUA means the FDA will allow some people to receive the vaccine as the agency continues to evaluate data. It isn’t the same as full approval, which requires more data and can typically take several months longer. Moderna has submitted only two months of follow-up safety data. The agency usually requires six months for full approval. The committee recommended emergency authorization of the vaccine for people who are 18 years old and older.

Member Dr. Michael Kurilla, an infectious disease expert with the National Institutes of Health, was the only member to not vote yes. He said he decided to abstain because he was “uncomfortable” endorsing the vaccine for everyone age 18 and older.

“In the midst of a pandemic and with limited vaccine supply, a blanket statement for individuals for 18 years and older is just too broad,” said Kurilla. “I’m not convinced for all of those age groups the benefits do actually outweigh the risk.”

Initial doses will be limited as manufacturing ramps up, with officials predicting it will take months to immunize everyone in the U.S. who wants to be vaccinated. The Centers for Disease Control and Prevention has provided states with an outline that recommends prioritizing health-care workers and nursing homes, but states can distribute the vaccine as they see fit.

Moderna’s vaccine uses messenger RNA, or mRNA, technology. It’s a new approach to vaccines that uses genetic material to provoke an immune response. Late-stage clinical trial data shows the vaccine is more than 94% effective in preventing Covid, is safe and appears to fend off severe disease. To achieve maximum effectiveness, the vaccine requires two doses taken four weeks apart.

The FDA has indicated it would authorize a Covid-19 vaccine that’s safe and at least 50% effective. The flu vaccine, by comparison, generally reduces people’s risk of getting influenza by 40% to 60% compared with people who aren’t inoculated, according to the CDC.

FDA staff endorsed Moderna’s vaccine on Tuesday, saying in documents that the clinical trial results and safety data were “consistent with the recommendations set forth in FDA’s Guidance on Emergency Use Authorization for Vaccines to Prevent COVID-19.”

Cont...


##https://www.cnbc.com/2020/12/17/moderna-covid-vaccine-fda-panel-recommends-emergency-approval.html

FDA panel endorses second Covid vaccine in U.S. as Moderna wins key vote in path to emergency use

(PUBLISHED THU, DEC 17 20205:00 PM ESTUPDATED THU, DEC 17 20207:05 PM EST)

~ An influential FDA advisory panel overwhelmingly voted to recommend the approval of Moderna’s coronavirus vaccine for emergency use.

~ The FDA’s Vaccines and Related Biological Products Advisory Committee plays a key role in approving flu and other vaccines in the U.S., verifying the shots are safe for public use.

~ While the FDA doesn’t have to follow the advisory committee’s recommendation, it often does.


An influential Food and Drug Administration advisory panel on Thursday overwhelmingly backed Moderna’s coronavirus vaccine, a key step paving the way to distribute the second Covid-19 vaccine in the United States next week.

The nonbinding decision, which was adopted 20-0 with one abstention, by the FDA’s Vaccines and Related Biological Products Advisory Committee came exactly a week after the outside group of vaccine and infectious disease experts voted to recommend Pfizer and BioNTech’s vaccine for an emergency use authorization, or EUA. The agency granted Pfizer’s EUA the next day, and the first inoculations in the U.S. were given Monday.

The FDA advisory committee plays a key role in approving flu and other vaccines in the U.S., verifying the shots are safe for public use. While the FDA doesn’t have to follow the advisory committee’s recommendation, it often does. The U.S. plans to ship just under 6 million doses next week, pending the agency’s OK, Gen. Gustave Perna, who oversees logistics for the Operation Warp Speed vaccine project, told reporters Monday.

Prior to the vote, some members of the committee stressed that their endorsement for Moderna’s vaccine was not for a full FDA approval, reiterating that the agency will still need to review more data on safety and effectiveness.

“I don’t want people to interpret this the same way they would a licensed vaccine,” said Dr. Cody Meissner, a voting member of the committee and an infectious diseases expert at Tufts University School of Medicine. The endorsement is “based on the available evidence, but that’s limited.”

An EUA means the FDA will allow some people to receive the vaccine as the agency continues to evaluate data. It isn’t the same as full approval, which requires more data and can typically take several months longer. Moderna has submitted only two months of follow-up safety data. The agency usually requires six months for full approval. The committee recommended emergency authorization of the vaccine for people who are 18 years old and older.

Member Dr. Michael Kurilla, an infectious disease expert with the National Institutes of Health, was the only member to not vote yes. He said he decided to abstain because he was “uncomfortable” endorsing the vaccine for everyone age 18 and older.

“In the midst of a pandemic and with limited vaccine supply, a blanket statement for individuals for 18 years and older is just too broad,” said Kurilla. “I’m not convinced for all of those age groups the benefits do actually outweigh the risk.”

Initial doses will be limited as manufacturing ramps up, with officials predicting it will take months to immunize everyone in the U.S. who wants to be vaccinated. The Centers for Disease Control and Prevention has provided states with an outline that recommends prioritizing health-care workers and nursing homes, but states can distribute the vaccine as they see fit.

Moderna’s vaccine uses messenger RNA, or mRNA, technology. It’s a new approach to vaccines that uses genetic material to provoke an immune response. Late-stage clinical trial data shows the vaccine is more than 94% effective in preventing Covid, is safe and appears to fend off severe disease. To achieve maximum effectiveness, the vaccine requires two doses taken four weeks apart.

The FDA has indicated it would authorize a Covid-19 vaccine that’s safe and at least 50% effective. The flu vaccine, by comparison, generally reduces people’s risk of getting influenza by 40% to 60% compared with people who aren’t inoculated, according to the CDC.

FDA staff endorsed Moderna’s vaccine on Tuesday, saying in documents that the clinical trial results and safety data were “consistent with the recommendations set forth in FDA’s Guidance on Emergency Use Authorization for Vaccines to Prevent COVID-19.”

Cont...


##https://www.cnbc.com/2020/12/17/moderna-covid-vaccine-fda-panel-recommends-emergency-approval.html

Post removed.Why?

Fed raises its economic outlook slightly, sees 4.2% growth next year and 5% unemployment rate

(PUBLISHED WED, DEC 16 20202:28 PM ESTUPDATED WED, DEC 16 20203:00 PM EST)

~ The Federal Reserve expects real gross domestic product to fall just 2.4% in 2020, compared to a decline of 3.7% predicted in September.

~ The Fed also upped its 2021 real GDP forecast to 4.2% from 4.0%.

~ The Jerome Powell-led Fed estimates the unemployment rate to fall to 6.7% this year, also an improvement from 7.6% projection in September.

The Federal Reserve dialed up its economic expectations slightly for the end of this year as well as for 2021, according to the central bank’s Summary of Economic Projections released on Wednesday.

The central bank now expects real gross domestic product to fall just 2.4% in 2020, compared to a decline of 3.7% predicted in September. The Fed also upped its 2021 real GDP forecast to 4.2% from 4.0% expected previously

The Jerome Powell-led Fed estimates the unemployment rate to fall to 6.7% this year, further below the 7.6% previously predicted. The unemployment rate should fall to 5.0% in 2021, compared to the central bank’s previous estimate of 5.5%.

The Federal Open Market Committee said in its statement Wednesday that it would continue to buy at least $120 billion of bonds each month “until substantial further progress has been made toward the Committee’s maximum employment and price stability goals.”

The Fed kept its inflation estimates for 2020 unchanged at 1.2%. The FOMC now sees PCE inflation running to 1.8% next year, slightly above its previous estimate of 1.7%.

Core PCE inflation is expected to come in at 1.4% this year, down slightly from September’s projection of 1.4%. Next year, core PCE inflation is estimated to reach 1.8%, up from September’s forecast of 1.7%.

The Fed decided to keep interest rates unchanged in its December meeting after slashing them to near-zero in an emergency meeting in March due to the fast-spreading coronavirus.


##https://www.cnbc.com/2020/12/16/fed-raises-its-economic-outlook-slightly-sees-4point2percent-growth-next-year-and-5percent-unemployment-rate.html

##https://www.theedgemarkets.com/article/sc-bursa-malaysia-lift-temporary-suspension-regulated-short-selling


^^ Everybody happy bombebe...

Ban on restricted short-selling to be lifted on Jan 1, but intraday short selling remains prohibited until Feb 28

(theedgemarkets.com / December 16, 2020 19:17 pm +08)


KUALA LUMPUR (Dec 16): The suspension of restricted short-selling (RSS) on Bursa Malaysia is set to be lifted on Jan 1 next year, after the sanction was imposed by the regulators for nine months.

However, the regulator extended the ban on the intraday short-selling (IDSS) and intraday short-selling by proprietary day traders (PDT Short Sale) until Feb 28, 2021. Consequential to the extension of PDT Short Sale, temporary waivers in relation to PDT will also be extended to Feb 28, 2021.

To recap, the ban on short selling of equities was imposed by the Securities Commission Malaysia (SC) and Bursa Malaysia starting on March 24 this year when global markets were hammered by the equity rout. The move, said the regulators, was “part of their proactive measures to mitigate potential risks arising from heightened volatility and global uncertainties.”

The suspension was initially targeted to end on April 30 but was extended for three times. At first it was targeted to end on June 30, but was extended till Dec 31, 2020 and it was further extended till Feb 28, 2021.

“The SC and Bursa Malaysia Bhd will lift the temporary suspension of Regulated Short Selling (RSS) and have reviewed other market management measures that were introduced this year following heightened market volatility arising from the broader impact of Covid-19.

“This decision was made after careful consideration of current market conditions and the evolving needs of the market,” according to the joint statement by SC and Bursa Malaysia.

It stated the move to lift the ban of RSS is to facilitate investors’ risk management and revive Securities Borrowing and Lending (SBL) activities, which is an integral capital market function to promote product development and market making activities.

Notwithstanding that, the RSS will be re-introduced with the following enhanced control measures to ensure stability and maintain investor confidence.

“The daily gross short position limit for approved securities will be temporarily reduced from 3% to 2%; and a new cap of 4% on RSS aggregated net short position will be introduced,” the statement showed.

Meanwhile, they said the temporary revisions to existing market management measures, namely the dynamic and static price limits as well as the circuit breaker, will be extended till May 30, 2021. These were implemented on July 20, 2020 and are due to expire on Jan 18, 2021.

##https://www.theedgemarkets.com/article/sc-bursa-malaysia-lift-temporary-suspension-regulated-short-selling


^^^Everyone happy!!!...

Ban on restricted short-selling to be lifted on Jan 1, but intraday short selling remains prohibited until Feb 28

(theedgemarkets.com / December 16, 2020 19:17 pm +08)


KUALA LUMPUR (Dec 16): The suspension of restricted short-selling (RSS) on Bursa Malaysia is set to be lifted on Jan 1 next year, after the sanction was imposed by the regulators for nine months.

However, the regulator extended the ban on the intraday short-selling (IDSS) and intraday short-selling by proprietary day traders (PDT Short Sale) until Feb 28, 2021. Consequential to the extension of PDT Short Sale, temporary waivers in relation to PDT will also be extended to Feb 28, 2021.

To recap, the ban on short selling of equities was imposed by the Securities Commission Malaysia (SC) and Bursa Malaysia starting on March 24 this year when global markets were hammered by the equity rout. The move, said the regulators, was “part of their proactive measures to mitigate potential risks arising from heightened volatility and global uncertainties.”

The suspension was initially targeted to end on April 30 but was extended for three times. At first it was targeted to end on June 30, but was extended till Dec 31, 2020 and it was further extended till Feb 28, 2021.

“The SC and Bursa Malaysia Bhd will lift the temporary suspension of Regulated Short Selling (RSS) and have reviewed other market management measures that were introduced this year following heightened market volatility arising from the broader impact of Covid-19.

“This decision was made after careful consideration of current market conditions and the evolving needs of the market,” according to the joint statement by SC and Bursa Malaysia.

It stated the move to lift the ban of RSS is to facilitate investors’ risk management and revive Securities Borrowing and Lending (SBL) activities, which is an integral capital market function to promote product development and market making activities.

Notwithstanding that, the RSS will be re-introduced with the following enhanced control measures to ensure stability and maintain investor confidence.

“The daily gross short position limit for approved securities will be temporarily reduced from 3% to 2%; and a new cap of 4% on RSS aggregated net short position will be introduced,” the statement showed.

Meanwhile, they said the temporary revisions to existing market management measures, namely the dynamic and static price limits as well as the circuit breaker, will be extended till May 30, 2021. These were implemented on July 20, 2020 and are due to expire on Jan 18, 2021.

##https://www.theedgemarkets.com/article/sc-bursa-malaysia-lift-temporary-suspension-regulated-short-selling

Ban on restricted short-selling to be lifted on Jan 1, but intraday short selling remains prohibited until Feb 28

(theedgemarkets.com / December 16, 2020 19:17 pm +08)


KUALA LUMPUR (Dec 16): The suspension of restricted short-selling (RSS) on Bursa Malaysia is set to be lifted on Jan 1 next year, after the sanction was imposed by the regulators for nine months.

However, the regulator extended the ban on the intraday short-selling (IDSS) and intraday short-selling by proprietary day traders (PDT Short Sale) until Feb 28, 2021. Consequential to the extension of PDT Short Sale, temporary waivers in relation to PDT will also be extended to Feb 28, 2021.

To recap, the ban on short selling of equities was imposed by the Securities Commission Malaysia (SC) and Bursa Malaysia starting on March 24 this year when global markets were hammered by the equity rout. The move, said the regulators, was “part of their proactive measures to mitigate potential risks arising from heightened volatility and global uncertainties.”

The suspension was initially targeted to end on April 30 but was extended for three times. At first it was targeted to end on June 30, but was extended till Dec 31, 2020 and it was further extended till Feb 28, 2021.

“The SC and Bursa Malaysia Bhd will lift the temporary suspension of Regulated Short Selling (RSS) and have reviewed other market management measures that were introduced this year following heightened market volatility arising from the broader impact of Covid-19.

“This decision was made after careful consideration of current market conditions and the evolving needs of the market,” according to the joint statement by SC and Bursa Malaysia.

It stated the move to lift the ban of RSS is to facilitate investors’ risk management and revive Securities Borrowing and Lending (SBL) activities, which is an integral capital market function to promote product development and market making activities.

Notwithstanding that, the RSS will be re-introduced with the following enhanced control measures to ensure stability and maintain investor confidence.

“The daily gross short position limit for approved securities will be temporarily reduced from 3% to 2%; and a new cap of 4% on RSS aggregated net short position will be introduced,” the statement showed.

Meanwhile, they said the temporary revisions to existing market management measures, namely the dynamic and static price limits as well as the circuit breaker, will be extended till May 30, 2021. These were implemented on July 20, 2020 and are due to expire on Jan 18, 2021.

Ban on restricted short-selling to be lifted on Jan 1, but intraday short selling remains prohibited until Feb 28

(theedgemarkets.com / December 16, 2020 19:17 pm +08)


KUALA LUMPUR (Dec 16): The suspension of restricted short-selling (RSS) on Bursa Malaysia is set to be lifted on Jan 1 next year, after the sanction was imposed by the regulators for nine months.

However, the regulator extended the ban on the intraday short-selling (IDSS) and intraday short-selling by proprietary day traders (PDT Short Sale) until Feb 28, 2021. Consequential to the extension of PDT Short Sale, temporary waivers in relation to PDT will also be extended to Feb 28, 2021.

To recap, the ban on short selling of equities was imposed by the Securities Commission Malaysia (SC) and Bursa Malaysia starting on March 24 this year when global markets were hammered by the equity rout. The move, said the regulators, was “part of their proactive measures to mitigate potential risks arising from heightened volatility and global uncertainties.”

The suspension was initially targeted to end on April 30 but was extended for three times. At first it was targeted to end on June 30, but was extended till Dec 31, 2020 and it was further extended till Feb 28, 2021.

“The SC and Bursa Malaysia Bhd will lift the temporary suspension of Regulated Short Selling (RSS) and have reviewed other market management measures that were introduced this year following heightened market volatility arising from the broader impact of Covid-19.

“This decision was made after careful consideration of current market conditions and the evolving needs of the market,” according to the joint statement by SC and Bursa Malaysia.

It stated the move to lift the ban of RSS is to facilitate investors’ risk management and revive Securities Borrowing and Lending (SBL) activities, which is an integral capital market function to promote product development and market making activities.

Notwithstanding that, the RSS will be re-introduced with the following enhanced control measures to ensure stability and maintain investor confidence.

“The daily gross short position limit for approved securities will be temporarily reduced from 3% to 2%; and a new cap of 4% on RSS aggregated net short position will be introduced,” the statement showed.

Meanwhile, they said the temporary revisions to existing market management measures, namely the dynamic and static price limits as well as the circuit breaker, will be extended till May 30, 2021. These were implemented on July 20, 2020 and are due to expire on Jan 18, 2021.

Ban on restricted short-selling to be lifted on Jan 1, but intraday short selling remains prohibited until Feb 28

(theedgemarkets.com / December 16, 2020 19:17 pm +08)


KUALA LUMPUR (Dec 16): The suspension of restricted short-selling (RSS) on Bursa Malaysia is set to be lifted on Jan 1 next year, after the sanction was imposed by the regulators for nine months.

However, the regulator extended the ban on the intraday short-selling (IDSS) and intraday short-selling by proprietary day traders (PDT Short Sale) until Feb 28, 2021. Consequential to the extension of PDT Short Sale, temporary waivers in relation to PDT will also be extended to Feb 28, 2021.

To recap, the ban on short selling of equities was imposed by the Securities Commission Malaysia (SC) and Bursa Malaysia starting on March 24 this year when global markets were hammered by the equity rout. The move, said the regulators, was “part of their proactive measures to mitigate potential risks arising from heightened volatility and global uncertainties.”

The suspension was initially targeted to end on April 30 but was extended for three times. At first it was targeted to end on June 30, but was extended till Dec 31, 2020 and it was further extended till Feb 28, 2021.

“The SC and Bursa Malaysia Bhd will lift the temporary suspension of Regulated Short Selling (RSS) and have reviewed other market management measures that were introduced this year following heightened market volatility arising from the broader impact of Covid-19.

“This decision was made after careful consideration of current market conditions and the evolving needs of the market,” according to the joint statement by SC and Bursa Malaysia.

It stated the move to lift the ban of RSS is to facilitate investors’ risk management and revive Securities Borrowing and Lending (SBL) activities, which is an integral capital market function to promote product development and market making activities.

Notwithstanding that, the RSS will be re-introduced with the following enhanced control measures to ensure stability and maintain investor confidence.

“The daily gross short position limit for approved securities will be temporarily reduced from 3% to 2%; and a new cap of 4% on RSS aggregated net short position will be introduced,” the statement showed.

Meanwhile, they said the temporary revisions to existing market management measures, namely the dynamic and static price limits as well as the circuit breaker, will be extended till May 30, 2021. These were implemented on July 20, 2020 and are due to expire on Jan 18, 2021.

##https://www.theedgemarkets.com/article/sc-bursa-malaysia-lift-temporary-suspension-regulated-short-selling

Ban on restricted short-selling to be lifted on Jan 1, but intraday short selling remains prohibited until Feb 28

(theedgemarkets.com / December 16, 2020 19:17 pm +08)


KUALA LUMPUR (Dec 16): The suspension of restricted short-selling (RSS) on Bursa Malaysia is set to be lifted on Jan 1 next year, after the sanction was imposed by the regulators for nine months.

However, the regulator extended the ban on the intraday short-selling (IDSS) and intraday short-selling by proprietary day traders (PDT Short Sale) until Feb 28, 2021. Consequential to the extension of PDT Short Sale, temporary waivers in relation to PDT will also be extended to Feb 28, 2021.

To recap, the ban on short selling of equities was imposed by the Securities Commission Malaysia (SC) and Bursa Malaysia starting on March 24 this year when global markets were hammered by the equity rout. The move, said the regulators, was “part of their proactive measures to mitigate potential risks arising from heightened volatility and global uncertainties.”

The suspension was initially targeted to end on April 30 but was extended for three times. At first it was targeted to end on June 30, but was extended till Dec 31, 2020 and it was further extended till Feb 28, 2021.

“The SC and Bursa Malaysia Bhd will lift the temporary suspension of Regulated Short Selling (RSS) and have reviewed other market management measures that were introduced this year following heightened market volatility arising from the broader impact of Covid-19.

“This decision was made after careful consideration of current market conditions and the evolving needs of the market,” according to the joint statement by SC and Bursa Malaysia.

It stated the move to lift the ban of RSS is to facilitate investors’ risk management and revive Securities Borrowing and Lending (SBL) activities, which is an integral capital market function to promote product development and market making activities.

Notwithstanding that, the RSS will be re-introduced with the following enhanced control measures to ensure stability and maintain investor confidence.

“The daily gross short position limit for approved securities will be temporarily reduced from 3% to 2%; and a new cap of 4% on RSS aggregated net short position will be introduced,” the statement showed.

Meanwhile, they said the temporary revisions to existing market management measures, namely the dynamic and static price limits as well as the circuit breaker, will be extended till May 30, 2021. These were implemented on July 20, 2020 and are due to expire on Jan 18, 2021.


##https://www.theedgemarkets.com/article/sc-bursa-malaysia-lift-temporary-suspension-regulated-short-selling

Ban on restricted short-selling to be lifted on Jan 1, but intraday short selling remains prohibited until Feb 28

(theedgemarkets.com / December 16, 2020 19:17 pm +08)


KUALA LUMPUR (Dec 16): The suspension of restricted short-selling (RSS) on Bursa Malaysia is set to be lifted on Jan 1 next year, after the sanction was imposed by the regulators for nine months.

However, the regulator extended the ban on the intraday short-selling (IDSS) and intraday short-selling by proprietary day traders (PDT Short Sale) until Feb 28, 2021. Consequential to the extension of PDT Short Sale, temporary waivers in relation to PDT will also be extended to Feb 28, 2021.

To recap, the ban on short selling of equities was imposed by the Securities Commission Malaysia (SC) and Bursa Malaysia starting on March 24 this year when global markets were hammered by the equity rout. The move, said the regulators, was “part of their proactive measures to mitigate potential risks arising from heightened volatility and global uncertainties.”

The suspension was initially targeted to end on April 30 but was extended for three times. At first it was targeted to end on June 30, but was extended till Dec 31, 2020 and it was further extended till Feb 28, 2021.

“The SC and Bursa Malaysia Bhd will lift the temporary suspension of Regulated Short Selling (RSS) and have reviewed other market management measures that were introduced this year following heightened market volatility arising from the broader impact of Covid-19.

“This decision was made after careful consideration of current market conditions and the evolving needs of the market,” according to the joint statement by SC and Bursa Malaysia.

It stated the move to lift the ban of RSS is to facilitate investors’ risk management and revive Securities Borrowing and Lending (SBL) activities, which is an integral capital market function to promote product development and market making activities.

Notwithstanding that, the RSS will be re-introduced with the following enhanced control measures to ensure stability and maintain investor confidence.

“The daily gross short position limit for approved securities will be temporarily reduced from 3% to 2%; and a new cap of 4% on RSS aggregated net short position will be introduced,” the statement showed.

Meanwhile, they said the temporary revisions to existing market management measures, namely the dynamic and static price limits as well as the circuit breaker, will be extended till May 30, 2021. These were implemented on July 20, 2020 and are due to expire on Jan 18, 2021.


##https://www.theedgemarkets.com/article/sc-bursa-malaysia-lift-temporary-suspension-regulated-short-selling

Wahhh...Keyman188 just realized.....

Keyman188' comments so powerful mehhh......

So influence until the share price up or down......

So naive...so dumb......

Aiya...better sell lahhh...better cut loss lahhh...


wkwkwk...kekeke......




Posted by a2333778 > Dec 16, 2020 4:54 PM | Report Abuse 

Keyman 188 's statement make shareholder sell it out unstoppable. No one like 'orang tua' and to keep the stocks for 10 to 30 years and for next generation.. Stocks keep for 6 months to 1 year considered making fast money?

Definition :-

"A long-term investment is an account on the asset side of a company's balance sheet that represents the company's investments, including stocks, bonds, real estate, and cash. Long-term investments are assets that a company intends to hold for more than a year"


"Depending on the type of security, a long-term asset can be held for as little as one year or for as long as 30 years or more. Generally speaking, long-term investing for individuals is often thought to be in the range of at least seven to ten years of holding time, although there is no absolute rule"



##https://www.investopedia.com/terms/l/longterm.asp

How do you feel today all shareholders ???......


KLCI already unstoppable rebounded from low 1207 until 1690.....


Only HLCap still heavily unstoppable selling pressure everyday......


Is it the time to escape unknown future stock ???......


Keyman188 already highlighted earlier......


This counter not suitable for those fast money players...


This counter is for storage purpose...is for "Orang Tua" keep it for the next 10 years or 20 years or 30 years...


Perhaps need to keep it for next generation asset......


Don't expect fast jump up like other fancy counters......


CHEERS..........................

Kossan founder says 427 employees tested positive for Covid-19, impacting less than 2% of bottom line

(theedgemarkets.com / December 16, 2020 15:29 pm +08)

KUALA LUMPUR (Dec 16): Despite 427 out of a total of 7,004 employees testing positive for Covid-19, Kossan Rubber Industries Bhd founder Tan Sri Lim Kuang Sia expects the impact to be less than 2% of the group's bottom line.

Lim confirmed with theedgemarkets.com that only one site out of the group’s six locations, or 25% of its total output volume, was affected by the outbreak.

“The impact on production is only for two weeks (starting from Dec 4). So, the impact on our profit is less than 2%,” he said.

According to Kenanga Research analyst Choo Ping Khoon, Kossan told analysts in a briefing yesterday that the group conducted a voluntary Covid-19 screening test at its glove division from Dec 4 to Dec 10.

“Out of a total of 7,004 workers, five out of six locations registered zero cases, with only one site reporting 427 positive cases out of 2,104 employees,” he said.

Citing management guidance, Choo said the factory had stopped its operations for sanitisation, which had since been completed.

He also said presently, the other 1,667 workers are undergoing quarantine and will undergo a second round of testing today and tomorrow, with the results expected to be released on Friday.

“Thereafter, the group will undergo random sampling for an antigen test for asymptomatic symptoms in every two weeks [for 20% of workers]. The operation is expected to gradually ramp up production by Dec 20.

“The temporary loss in production comprised 25% of total output volume for two weeks, which is expected to impact the FY20 (financial year ending Dec 31, 2020) estimated bottom line by 2%,” Choo said.

Choo maintained his "outperform" call for Kossan with an unchanged target price (TP) of RM9.36.

Affin Hwang Capital analyst Ng Chi Hoong also quoted the management as saying the group’s overall average selling price (ASP) would increase by at least 50% in the fourth quarter of 2020 (4Q20) and 30% to 35% in 1Q21.

He maintained his "buy" call and TP of RM8.90 for the stock as he was not overly concerned about potential oversupply occurring in 2022.

“We believe that existing players will have a cost advantage against new entrants due to their highly automated production lines. Current strong relationships with established distributors also allow them to sell their products at a premium,” he said.

AmInvestment Bank analyst Thong Pak Leng also said he likes Kossan as it is one of the biggest glove producers to benefit from the Covid-19 pandemic due to its expansionary plans and efforts in improving quality and operational efficiency.

“Our fair value (FV) of RM5.40 is based on 27 times (the five-year average) price-earnings ratio (PER) over FY22 earnings per share (EPS),” said Thong, who maintained his "hold" call for the counter.

He also raised his FY21 net profit forecast for Kossan by 46% after imputing higher ASPs.

“We increase our ASP assumption to US$40/1,000 pieces from US$34/1,000 pieces. However, we cut [our] FY22 earnings [forecast] by 23% with [our] ASP assumption reduced to US$29/1,000 pieces from US$30/1,000 pieces. We make no changes to our FY20 numbers,” he said.


##https://www.theedgemarkets.com/article/kossan-founder-says-427-employees-tested-positive-covid19-impacting-less-2-bottom-line

Kossan founder says 427 employees tested positive for Covid-19, impacting less than 2% of bottom line

(theedgemarkets.com / December 16, 2020 15:29 pm +08)

KUALA LUMPUR (Dec 16): Despite 427 out of a total of 7,004 employees testing positive for Covid-19, Kossan Rubber Industries Bhd founder Tan Sri Lim Kuang Sia expects the impact to be less than 2% of the group's bottom line.

Lim confirmed with theedgemarkets.com that only one site out of the group’s six locations, or 25% of its total output volume, was affected by the outbreak.

“The impact on production is only for two weeks (starting from Dec 4). So, the impact on our profit is less than 2%,” he said.

According to Kenanga Research analyst Choo Ping Khoon, Kossan told analysts in a briefing yesterday that the group conducted a voluntary Covid-19 screening test at its glove division from Dec 4 to Dec 10.

“Out of a total of 7,004 workers, five out of six locations registered zero cases, with only one site reporting 427 positive cases out of 2,104 employees,” he said.

Citing management guidance, Choo said the factory had stopped its operations for sanitisation, which had since been completed.

He also said presently, the other 1,667 workers are undergoing quarantine and will undergo a second round of testing today and tomorrow, with the results expected to be released on Friday.

“Thereafter, the group will undergo random sampling for an antigen test for asymptomatic symptoms in every two weeks [for 20% of workers]. The operation is expected to gradually ramp up production by Dec 20.

“The temporary loss in production comprised 25% of total output volume for two weeks, which is expected to impact the FY20 (financial year ending Dec 31, 2020) estimated bottom line by 2%,” Choo said.

Choo maintained his "outperform" call for Kossan with an unchanged target price (TP) of RM9.36.

Affin Hwang Capital analyst Ng Chi Hoong also quoted the management as saying the group’s overall average selling price (ASP) would increase by at least 50% in the fourth quarter of 2020 (4Q20) and 30% to 35% in 1Q21.

He maintained his "buy" call and TP of RM8.90 for the stock as he was not overly concerned about potential oversupply occurring in 2022.

“We believe that existing players will have a cost advantage against new entrants due to their highly automated production lines. Current strong relationships with established distributors also allow them to sell their products at a premium,” he said.

AmInvestment Bank analyst Thong Pak Leng also said he likes Kossan as it is one of the biggest glove producers to benefit from the Covid-19 pandemic due to its expansionary plans and efforts in improving quality and operational efficiency.

“Our fair value (FV) of RM5.40 is based on 27 times (the five-year average) price-earnings ratio (PER) over FY22 earnings per share (EPS),” said Thong, who maintained his "hold" call for the counter.

He also raised his FY21 net profit forecast for Kossan by 46% after imputing higher ASPs.

“We increase our ASP assumption to US$40/1,000 pieces from US$34/1,000 pieces. However, we cut [our] FY22 earnings [forecast] by 23% with [our] ASP assumption reduced to US$29/1,000 pieces from US$30/1,000 pieces. We make no changes to our FY20 numbers,” he said.


##https://www.theedgemarkets.com/article/kossan-founder-says-427-employees-tested-positive-covid19-impacting-less-2-bottom-line

Keyman188 always like to repeat & repeat again to the market...


Padini among the retail company is the most stronger...


So fast on the road of recovery...QoQ up 223% & YoY up 5.67% during current unprecedented pandemic period...


Furthermore, company net cash position also increased from RM 439.855 million to RM 511.691 million...


Quality of earnings also improved to 5.19 times


Past 10 years can produce average of 20% ROE...


If based on the latest announcement by company, dividend still under company preview...


Consistent dividend payout for the past 10 years (except this year need to set more cash pile to tackle upcoming unprecedented incident)...


Dividend yield shall be achievable about 5.6% (based on Keyman188 entry cost) once current pandemic over & upcoming seasonal period...


Consumer sector is the fastest sector on the recovery road...


Be more tolerance & patience to wait dividend payout for upcoming period...


Keyman188 no plan to sell.......


See you @ 5.00......


See you give Keyman188 bonus reward......



CHEERS.....................................

AmInvestment Bank sees KLCI hitting 1,770 points at end-2021

(theedgemarkets.com / December 16, 2020 11:03 am +08)

KUALA LUMPUR (Dec 16): AmInvestment Bank estimated that the FBM KLCI will hit 1,770 points at end-2021, based on 17.5 times its 2021 earnings projections or an increase of 45.9%.

The research house’s head of equity research Joshua Ng said in a report today the outlook for equity markets globally, with Malaysia included, is positive for 2021, driven largely by optimism about a synchronised global economic recovery as the world emerges from the Covid-19 pandemic.

He believes the recovery-focused investment theme from end-2020 will extend well into 2021.

“Investors will continue to accumulate recovery plays, i.e. fundamentally strong names in the banking, power, oil and gas (O&G), consumer, REIT (real estate investment trust) and transport sectors, while lightening their positions in pandemic plays, i.e. glove makers and selected excessively priced technology names,” he said.

While the KLCI could be lifted higher as investors chase recovery plays, particularly the index-heavy banking stocks, he noted there could potentially be a drag from weakness in share prices of pandemic plays, particularly glove stocks.

Ng added that the fundamentals of banking stocks should improve in line with the economic recovery.

“While clarity is still lacking with regard to the extent of the irreversible damage the pandemic has inflicted on businesses, and hence asset quality of banks, we take comfort that banks have started to make pre-emptive provisions in the form of management overlays, in addition to provisions based on changes to macroeconomic factors,” he said.

According to Ng, other key sectors poised to benefit from the recovery are power (increased demand for electricity, particularly from the commercial and industrial segments), O&G (higher crude oil prices), seaport (higher throughput on the recovery in global trade), airport (the eventual reopening of borders), consumer (cash handouts and a recovery in the job market to sustain consumption) and REIT (reduced rental rebates, as well as a recovery in footfall and occupancy).

“While the availability of effective vaccines has greatly brightened recovery prospects of the air travel sector, we remain mindful of the need for airlines to recapitalise their balance sheet after months of massive losses during the pandemic,” he added.


BNM expected to hold OPR at 1.75% in 2021

Ng also expects Bank Negara Malaysia (BNM) to hold its benchmark overnight policy rate (OPR) at 1.75% throughout 2021, in line with the accommodative monetary policy stance expected from key central banks in the world in 2021.

He opined that the sustained low-interest-rate environment, coupled with the recovery narrative, will continue to make equities an attractive asset class for local investors.

He also expects domestic liquidity from both institutional and retail investors to remain robust in 2021, which shall continue to neutralise foreign selling, if any, as it did in 2020.

“We acknowledge that our market has been flying under the radar of foreign investors [due to Malaysia’s insignificant and shrinking weighting in the MSCI Emerging Markets Index and the market’s inherently high valuations, coupled with a lack of tech start-up listings].

“On the flip side, there is a silver lining to low foreign participation in the local market. Dominated by local participants, the market has remained calm in the face of a dynamic local political landscape,” he said.

Sector-wise, he is "overweight" on automobile, consumer, electronic manufacturing services (EMS), financial, healthcare, O&G, power, REITs, telco and transport.

His top picks reflect names that are likely to benefit from the recovery of the domestic and global economies, i.e. Malayan Banking Bhd (Malayan Banking Bhd), Tenaga Nasional Bhd (TNB), Axiata Group Bhd, RHB Bank Bhd, Dialog Group Bhd, Westports Holdings Bhd, Malaysia Airports Holdings Bhd (MAHB), IGB REIT, MMC Corp Bhd and Kumpulan Powernet Bhd.


##https://www.theedgemarkets.com/article/aminvestment-bank-sees-klci-hitting-1770-points-end2021

Dow jumps more than 300 points on stimulus optimism, S&P 500 snaps 4-day losing streak

(PUBLISHED MON, DEC 14 20206:03 PM ESTUPDATED TUE, DEC 15 20206:09 PM EST)

Stocks rose sharply on Tuesday as traders grew more optimistic about Congress passing another economic relief package.

The Dow Jones Industrial Average gained 337.76 points, or 1.1%, to 30,199.31. The S&P 500 advanced 1.3%, or 47.13 points, to 3,694.62, snapping a four-day losing streak. The Nasdaq Composite climbed 1.3%, or 155.02 points, to 12,595.06, reaching a new record closing high.

Apple led the Dow higher, jumping 5% after Nikkei reported the company will increase iPhone production by about 30% in the first half of 2021. All 11 S&P 500 sectors registered gains on Tuesday, led by energy and utilities.

The top four congressional leaders were set to meet at 4 p.m. Tuesday, seeking to reach an agreement on another round of coronavirus aid. House Speaker Nancy Pelosi set up the meeting with Senate Majority Leader Mitch McConnell, Senate Minority Leader Chuck Schumer and House Minority Leader Kevin McCarthy, marking the biggest effort yet to come to a bipartisan agreement.

The lawmakers released a proposal for another round of economic relief on Monday evening, splitting a previous measure into two parts.

The new plan calls for $748 billion in spending for programs that are popular on both sides of the aisle, including small business loans, unemployment insurance, vaccine distribution, education and rental assistance. A second $160 billion bill would include the more contentious areas of business liability protections and financial aid to state and local governments.

“There’s been a tug of war between the vaccine news and the virus news. The only tiebreaker that’s kept the averages on their way higher seems to be the potential for getting stimulus out of gridlock,” said Art Hogan, chief market strategist at National Securities. “It certainly feels like one of the proposals that’s on the table ... can go through.”

The latest step toward a stimulus deal comes as investors and Americans at large grapple with a bleak near-term outlook but prospects of economic growth and a possible end of the pandemic in 2021.

The first round of shots from the vaccine developed by Pfizer and BioNTech were given in the U.S. on Monday, but the country also passed 300,000 deaths from Covid-19, according to data from Johns Hopkins University. New York City Mayor Bill de Blasio also warned residents that a full shutdown may be needed to protect the city’s hospitals.

Luke Tilley, chief economist at Wilmington Trust, said that another stimulus package was needed to keep the economic recovery from stalling before the vaccine can be distributed.

“With the continued rising cases and mass vaccinations still a ways out, we could see some further weakness in jobs and even a flattening where we’re not even adding jobs at all ... that’s absolutely a possibility for this next jobs report,” Tilley said. “And if we were to not get another stimulus package, you’re going to have 10 to 11 million people fall off the unemployment rolls right away, and that would hit spending as well.”

On Tuesday morning, the Food and Drug Administration said the data on Moderna’s coronavirus vaccine met expectations for emergency use, a crucial step before a full approval. If the FDA greenlights the vaccine, it would be the second approved for use in the U.S. behind Pfizer’s.

The S&P 500 has gained more than 14% for the year despite the ongoing pandemic, leading some to believe that near-term upside could be limited.

“We may have already gotten a little bit of a Santa Claus rally,” David Waddell, chief investment strategist at wealth advisory firm Waddell and Associates. “So normally the markets would accelerate from here into year-end, and they may again, but the run has been such a strong one, I wouldn’t be surprised, and actually I’d rather, if the market consolidated its gains a little bit.”


##https://www.cnbc.com/2020/12/14/stock-market-futures-open-to-close-news.html

Keyman188 always like to repeat & repeat again to the market......


This counter not suitable for those fast money players...



This counter is for storage purpose...is for "Orang Tua" keep it for the next 10 years or 20 years or 30 years...



Don't expect fast jump up like other fancy counters...



You see Keyman188' HLFG today...already break 18.00 liao...cheers...

Sooner or later sure a lot of people will say...

Unbelievable...

已经怀疑了人生 !!!......

Keyman188 always say...Time will tell the market truth...

##https://www.bloomberg.com/news/articles/2020-12-15/moderna-vaccine-found-safe-effective-ahead-of-key-fda-review?srnd=premium-asia

Moderna Vaccine Found Safe, Effective Ahead of Key FDA Review


(December 15, 2020, 9:07 PM GMT+8)


~ Shot is 94.1% effective in preventing Covid, FDA report says

 
~ Advisory committee to weigh shot’s merits ahead of clearance


Moderna Inc.’s vaccine is safe and effective for preventing Covid-19, U.S. regulators said, clearing the way for a second shot to quickly gain emergency authorization and add to the country’s sprawling immunization effort.

The Food and Drug Administration’s staff said in a report on Tuesday that the experimental vaccine is 94.1% effective at preventing symptomatic Covid-19, confirming earlier results released by the company.

The report was posted online ahead of a meeting Thursday of agency advisers who will vote whether to recommend authorization before a final FDA decision. The agency doesn’t have to follow the advice of the independent vaccine experts, though it often agrees with its advisory panels. Last week, the FDA authorized a similar vaccine from Pfizer Inc. and BioNTech SE after an advisory panel voted 17-4, with one abstention, to support its authorization.


The FDA got a much deeper look at Moderna’s clinical-trial data than the numbers previously released to the public by the company. Notably, the agency was able to review the shot’s effectiveness across a broad range of racial, ethnic and age groups, and look at evidence of how well the shot worked for people with pre-existing medical conditions that make them more vulnerable to severe Covid-19.

Moderna Vaccine Found Safe, Effective Ahead of Key FDA Review


(December 15, 2020, 9:07 PM GMT+8)


~ Shot is 94.1% effective in preventing Covid, FDA report says

 
~ Advisory committee to weigh shot’s merits ahead of clearance


Moderna Inc.’s vaccine is safe and effective for preventing Covid-19, U.S. regulators said, clearing the way for a second shot to quickly gain emergency authorization and add to the country’s sprawling immunization effort.

The Food and Drug Administration’s staff said in a report on Tuesday that the experimental vaccine is 94.1% effective at preventing symptomatic Covid-19, confirming earlier results released by the company.

The report was posted online ahead of a meeting Thursday of agency advisers who will vote whether to recommend authorization before a final FDA decision. The agency doesn’t have to follow the advice of the independent vaccine experts, though it often agrees with its advisory panels. Last week, the FDA authorized a similar vaccine from Pfizer Inc. and BioNTech SE after an advisory panel voted 17-4, with one abstention, to support its authorization.


The FDA got a much deeper look at Moderna’s clinical-trial data than the numbers previously released to the public by the company. Notably, the agency was able to review the shot’s effectiveness across a broad range of racial, ethnic and age groups, and look at evidence of how well the shot worked for people with pre-existing medical conditions that make them more vulnerable to severe Covid-19.


##https://www.bloomberg.com/news/articles/2020-12-15/moderna-vaccine-found-safe-effective-ahead-of-key-fda-review?srnd=premium-asia

Moderna Vaccine Found Safe, Effective Ahead of Key FDA ReviewBy 


(December 15, 2020, 9:07 PM GMT+8)


~ Shot is 94.1% effective in preventing Covid, FDA report says

 
~ Advisory committee to weigh shot’s merits ahead of clearance


Moderna Inc.’s vaccine is safe and effective for preventing Covid-19, U.S. regulators said, clearing the way for a second shot to quickly gain emergency authorization and add to the country’s sprawling immunization effort.

The Food and Drug Administration’s staff said in a report on Tuesday that the experimental vaccine is 94.1% effective at preventing symptomatic Covid-19, confirming earlier results released by the company.

The report was posted online ahead of a meeting Thursday of agency advisers who will vote whether to recommend authorization before a final FDA decision. The agency doesn’t have to follow the advice of the independent vaccine experts, though it often agrees with its advisory panels. Last week, the FDA authorized a similar vaccine from Pfizer Inc. and BioNTech SE after an advisory panel voted 17-4, with one abstention, to support its authorization.


The FDA got a much deeper look at Moderna’s clinical-trial data than the numbers previously released to the public by the company. Notably, the agency was able to review the shot’s effectiveness across a broad range of racial, ethnic and age groups, and look at evidence of how well the shot worked for people with pre-existing medical conditions that make them more vulnerable to severe Covid-19.


##https://www.bloomberg.com/news/articles/2020-12-15/moderna-vaccine-found-safe-effective-ahead-of-key-fda-review?srnd=premium-asia

What happen ???


Why Suddenly soften again....


OMG...heading below 6.00 soon !!!......

This counter right now not "Time in the market"......

This counter already "Timing for the market" by big boys earlier......

Time will tell market the "Truth" soon...

Siapa dengar siapa kena kaw kaw later...

This fellow sure sudah stuck lorrr...

Keyman188 wants to see if the share price drop back to the range 2.00 ~ 2.30 for the next 12 month...then ding dong ding dong this range another 2 /3 years....

Foresee a lot of talk cock fellow sure disappear...


wkwkwk...wkwkwk..kekeke...kekeke.....


Posted by lee9fold > Dec 15, 2020 2:13 PM | Report Abuse

James89 No worry just sapu. Sure win in January.
15/12/2020 1:22 PM

yakah? if further drop how?